Medivation to raise $175 million as MDV3100 nears filing
This article was originally published in Scrip
Medivation is offering $175 million worth of convertible senior notes due 1 April 2017, with an additional $26.25 million available to the underwriters. The notes can be redeemed for cash from 6 April 2015.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.